Recombinant eEF1A1/EF-Tu Antibody - Primary antibody, specific to EEF1A1, Rabbit IgG

Cat. No.: Ab100992

GRADE & PURITY Recombinant, ExactAb™, Validated, See COA

Application

WB

Host species

Rabbit

Reactive species

Human, Mouse, Rat

Isotype

Rabbit IgG

Conjugation

Unconjugated

Overview

Rabbit anti Human eEF1A1/EF-Tu Antibody, Recombinant, could be used for WB and so on.

Specifications

Product Name

Recombinant eEF1A1/EF-Tu Antibody - Primary antibody, specific to EEF1A1, Rabbit IgG

Synonyms

Elongation factor 1-alpha 1 | EF-1-alpha-1 | Elongation factor Tu (EF-Tu) | Eukaryotic elongation factor 1 A-1 (eEF1A-1) | Leukocyte receptor cluster member 7 | EF1A1_HUMAN | EEF1A | EF1A | LENG7 | CCS 3 antibody | CCS3 antibody | Cervical cancer suppress

Specifications & Purity

Recombinant, ExactAb™, Validated, See COA

Biochemical and Physiological Mechanisms

This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis.

Host species

Rabbit

Specificity

EEF1A1

Immunogen

A synthetic peptide derived from human eEF1A1 (AA 401-462)

Positive Control

WB: HeLa, Jurkat and Hep G2 cell lysates.

Conjugation

Unconjugated

Grade

ExactAb™, Recombinant, Validated

Isotype

Rabbit IgG

Light Chain Type

kappa

SDS-PAGE

150 kDa

Purification Method

Protein A purified

Concentration

See COA

Product Line

Biological Products

Storage and Shipping

Shape

Liquid

Storage

Store at -20°C,Avoid repeated freezing and thawing

Shipped In

Ice chest + Ice pads

Stability And Storage

Store at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Images

Western Blot: Recombinant eEF1A1/EF-Tu Antibody (Ab100992)

Recombinant eEF1A1/EF-Tu Antibody (Ab100992) - Western Blot
All lanes: Recombinant eEF1A1/EF-Tu Antibody (Ab100992) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution
Predicted band size: 50 kDa
Observed band size: 47 kDa
Exposure time: 3.0 s

Application

Application

Dilution info

WB

1/1000-1/2000

Associated Targets(Human)

EEF1A1 Tchem Elongation factor 1-alpha 1 (0 Activities)

Discover Target: EEF1A1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mechanisms of Action

Application Protocols

Tested applications, recommended dilutions, and positive controls for SKU Ab100992 are not specified in the provided Product Data.

Per non-negotiable rules, only product-data-verified protocols can be listed here. Please refer to the CoA/Spec Sheet for:

• Validated applications (e.g., WB, IHC, IF, ELISA, IP) for this exact antibody.
• Recommended working dilutions and incubation conditions.
• Species reactivity and sample preparation guidance.
• Positive/negative control materials and expected band sizes or staining patterns.

Until item-specific data are reviewed, users should perform pilot titrations and standard assay optimization with appropriate controls.

Biological Roles

Target overview (general literature context; not product-specific claims)

• eEF1A1 (eukaryotic elongation factor 1A1): A highly abundant cytosolic GTPase that delivers aminoacyl-tRNAs to the ribosomal A-site during translation elongation. Beyond canonical roles, eEF1A1 has reported functions in actin bundling, nuclear export, and signal transduction, with multiple post-translational modifications influencing activity and localization.
• EF-Tu (elongation factor Tu): The bacterial homolog of eEF1A, also a GTPase that escorts aminoacyl-tRNA to the ribosome. EF-Tu is among the most abundant proteins in bacteria and is essential for protein synthesis; it participates in fidelity control by coupling GTP hydrolysis to codon–anticodon recognition.

Research utility

• Because of their abundance and conservation, eEF1A1 and EF-Tu are frequently used as loading or normalization controls in proteomics and as markers for translational capacity. They also serve as baits for studying translation factor interactomes and GTPase regulation.

Implications for experimental design

• Subcellular localization: Predominantly cytosolic; consider permeabilization for immunostaining. For bacterial EF-Tu, fixation conditions should preserve antigenicity.
• Isoforms and homologs: eEF1A has paralogs (e.g., eEF1A1 and eEF1A2) with overlapping but distinct expression profiles; ensure antibody epitope specificity if distinguishing isoforms is required. Specific cross-reactivity information for Ab100992 is not provided; refer to CoA/Spec Sheet.

Buffer Applications

This product is an antibody reagent rather than a buffering agent. Classical buffer system design (pKa, buffering ranges) is not applicable.

Practical buffer guidance for antibody use (general)

• Storage buffer: Neutral pH buffers (PBS, TBS) with stabilizers (e.g., 10–50% glycerol, 0.02–0.05% sodium azide, 0.1% carrier proteins) are commonly used to maintain stability and reduce adsorption; the exact composition for Ab100992 is not specified; refer to CoA.
• Assay buffers: For WB and ELISA, include blocking proteins (BSA, casein) and mild detergents (Tween-20) to minimize nonspecific binding. For IF/ICC, use appropriate permeabilization (e.g., saponin for gentle, Triton X-100 for robust) and blocking matched to species of the secondary antibody.
• Compatibility: Avoid chelators or low Mg2+ if preserving translation factor interactions in IP; ionic strength and divalent cations can influence complex stability.

Note: For lot-specific buffer composition, recommended diluents, and any preservative content, consult the CoA/Spec Sheet.

Green Alternatives

Sustainability considerations for antibody reagents focus on sourcing, formulation, and workflow rather than solvent replacement.

Greener attributes (general context)

• Recombinant production: Avoids animal immunization and ascites, reducing animal use and batch variability. Facilitates consistent yields and quality, reducing waste from failed experiments.
• Concentrated formats/lyophilization: When available, reduce cold-chain mass and shipping impact; enable room-temperature shipment in some cases. Format for this SKU is not specified; refer to CoA.
• Stabilizer selection: Formulations without azide or with low-toxicity preservatives can reduce hazardous waste. Composition is not specified for this item.

Operational practices

• Minimize single-use plastics by using reusable buffer reservoirs and calibrated multipipettes where appropriate.
• Optimize assay conditions to reduce antibody consumption (e.g., checkerboard titration), lowering overall material use.
• Prefer phosphate or HEPES buffers over Tris when wastewater salinity constraints apply; avoid excessive solvent use in membrane stripping or fixation when alternatives perform comparably.

Trade-offs

• Preservatives like sodium azide ease storage but add hazardous waste streams; glycerol improves freeze–thaw stability but increases shipping mass. Balance stability with environmental impact based on your workflow.

For SKU Ab100992, consult the CoA/Spec Sheet for formulation details that influence waste classification and disposal requirements.

Pharmaceutical Uses

This product is designated for research use only and is not intended for diagnostic or therapeutic applications.

Formulation and manufacturing context (general information)

• Recombinant antibodies are widely used as analytical raw materials in bioprocess development (e.g., reference reagents, in-process controls) and for platform method development (ELISA, ligand-binding assays). Such uses require well-characterized materials with consistent performance.
• Excipient considerations: Stabilizers like sugars, polyols, and amino acids are common in antibody formulations to maintain higher-order structure and reduce aggregation. Specific excipients for Ab100992 are not specified.
• Regulatory context: Research-grade antibodies are not produced under cGMP unless explicitly stated; no pharmacopeial monograph applies unless specified by the supplier. For any use in regulated workflows, qualification/bridging to GMP-grade materials is typically required.

For SKU Ab100992, no pharmacopeial status, excipient list, or clinical applicability is provided. Refer to CoA/Spec Sheet for detailed composition and to the SDS for safety considerations.

Physical Properties

Item-specific physico-chemical specifications are not provided for this antibody.

Item-specific facts (from Product Data)

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Concentration/formulation: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature properties for recombinant IgG antibodies (for context; not product specifications)

• Approximate MW: ~150 kDa for full-length IgG; smaller for fragments (Fab ~50 kDa, scFv ~25–30 kDa).
• Isoelectric point (pI): Often in the 6–9 range; depends on sequence and formulation excipients.
• Solubility: Highly soluble in aqueous buffers (PBS, Tris, HEPES) with stabilizers (e.g., 0.01–0.05% Tween-20, sugars, carrier proteins) to prevent adsorption and aggregation.
• Stability: Enhanced by storage at ≤−20°C, protection from repeated freeze–thaw cycles, and avoidance of prolonged exposure to elevated temperatures.
• UV absorbance: A280 commonly used to quantify; typical extinction coefficients depend on sequence (calculated from amino acid composition).

Practical notes

• If provided lyophilized, reconstitute with sterile buffer recommended on the CoA. If provided as a liquid, store aliquots to maintain integrity. For precise physical parameters (buffer composition, pH, protein concentration), consult the CoA/Spec Sheet for this lot.

Quality & Grades

Item-specific quality designations (from Product Data)

• Grade/Purity: Recombinant, ExactAb™, Validated.

What these mean in practice (general definitions; not additional specifications)

• Recombinant: Produced from a defined DNA sequence in a controlled expression system (e.g., HEK/CHO). Benefits include lot-to-lot consistency, absence of host animal variability, and potential elimination of undesired isotypes or off-target polyreactivity.
• ExactAb™: Branding that typically denotes sequence-defined, high-reproducibility antibody manufacturing with rigorous in-process controls. It implies precise control over variable regions and Fc format. Specific platform criteria for this product are not specified; refer to CoA/Spec Sheet.
• Validated: Indicates the antibody has undergone functional validation. The manufacturer applications and validation datasets for this specific SKU are not listed in the provided data; consult the CoA/datasheet for validated applications, species reactivity, and sample images.

Analytical controls typically associated with validated recombinant antibodies (general)

• Identity: Sequence verification, mass checks, and binding to target antigen.
• Purity: SDS-PAGE/Coomassie, SEC-HPLC for monomer content, low aggregate levels (values not specified for this item).
• Functional: Affinity/avidity measurements (e.g., ELISA, SPR/BLI), and application-specific validation (WB, IHC, IF, IP) where applicable.

Documentation

• For exact concentration, buffer composition, excipients, and validation scope for Ab100992, please refer to the CoA/Spec Sheet.

Reaction & Applications

As an analytical reagent antibody, this product is intended for detection and capture of its target proteins rather than for chemical reactions.

General research applications for antibodies targeting eEF1A1/EF-Tu (context; not item-specific validation)

• Western blot (WB): Detect eEF1A1 in eukaryotic cell lysates; EF-Tu in bacterial lysates. Optimize load and transfer for abundant cytosolic proteins. Denaturation conditions may affect epitope; test reducing vs non-reducing.
• Immunofluorescence (IF)/Immunocytochemistry (ICC): Visualize cytosolic localization of eEF1A1; in bacteria, EF-Tu is abundant and can serve as a loading or morphological marker. Permeabilization (e.g., 0.1–0.3% Triton X-100 or saponin) is commonly required.
• Immunoprecipitation (IP)/Co-IP: Enrich eEF1A1 complexes to study translation-associated interactors; maintain Mg2+/nucleotide conditions to preserve associations if desired.
• ELISA: Quantify antigen or validate binding affinity using recombinant eEF1A1/EF-Tu fragments or peptides.
• Flow cytometry: Typically less common for these cytosolic targets unless cells are fixed/permeabilized.

Practical tips (general)

• Titer and dilution must be empirically determined for each assay and sample type.
• Include species-matched isotype controls and secondary antibody controls to assess specificity and background.
• Use protease/phosphatase inhibitors in lysates if probing post-translationally modified forms.

Note: Specific validated applications for SKU Ab100992 are not provided in the Product Data; consult the CoA/Spec Sheet for confirmed use-cases.

Reaction Conditions

Conventional reaction-condition tables (solvent, temperature, catalysts) are not applicable to antibodies. For assay performance, consider the following general experimental conditions for immunoassays (context; not SKU-specific specifications):

General conditions for common applications

• Western blot: Denaturing SDS-PAGE, transfer to PVDF/nitrocellulose, blocking in 3–5% BSA or milk, primary antibody incubation at 4°C overnight or RT 1–2 h, followed by species-specific secondary.
• Immunofluorescence/ICC: Fix with PFA (3–4%) or methanol (−20°C) depending on epitope; permeabilize (0.1–0.3% Triton X-100 or saponin), block in serum/BSA, incubate primary at optimized dilution.
• IP/Co-IP: Non-denaturing lysis buffers (e.g., 1% NP-40 or 0.5% Triton X-100 in TBS), protease inhibitors; incubate lysate with antibody and Protein A/G resin.
• ELISA: Coating antigen on high-binding plates, block, primary incubation, HRP/TMB detection, read at 450 nm.

Parameters to optimize

• Antibody dilution, incubation time and temperature, blocking agent type, and salt/detergent levels. eEF1A1/EF-Tu abundance often enables lower antibody amounts, but optimal conditions are sample-dependent.

Note: Validated conditions for Ab100992 are not provided in the Product Data. Consult the CoA/Spec Sheet for any lot-specific recommendations.

Safety & Handling

Item-specific hazard information

• GHS classification: Not specified for this item; refer to SDS.
• Signal word: Not specified for this item; refer to SDS.
• H-statements and pictograms: Not specified for this item; refer to SDS.

General safety guidance for laboratory antibodies (non-sterile, research use)

• Typical hazards: Antibody preparations are generally considered low hazard; however, handle as potentially bioactive proteins. Formulations may contain preservatives (e.g., sodium azide) or glycerol—review SDS for exact composition and hazards.
• PPE: Wear lab coat, nitrile gloves, and safety glasses. Avoid inhalation of aerosols and contact with skin or eyes. Use biological safety cabinet if sterility is required or if handling biological materials.
• Incompatibilities: Avoid strong oxidizers and extreme pH that can denature proteins. Do not mix with crosslinking agents unless intended for conjugation.
• First aid (general): In case of skin/eye contact, rinse with water for 15 minutes. If inhaled, move to fresh air. If ingested, rinse mouth and seek medical advice. Always follow institutional biosafety procedures.
• Spills: Absorb with inert material, wash area with aqueous detergent. Dispose of waste according to local regulations and institutional guidelines.

Storage and transport

• Storage: Store at −20°C. Avoid repeated freeze–thaw (see Storage & Reconstitution).
• Shipping: Shipped cold (ice chest + ice pads) per Product Data to preserve activity.

Authoritative source: Defer to the product SDS and CoA for definitive safety and handling requirements.

Solvent Selection

This product is an aqueous protein reagent, not a small-molecule solute. Organic solvent selection is typically not applicable.

Applicable considerations for antibody handling (general guidance)

• Preferred medium: Physiological aqueous buffers (e.g., PBS, TBS, HEPES) at neutral pH help maintain structure and binding activity.
• Additives: Small amounts of non-ionic detergents (e.g., 0.01–0.05% Tween-20) reduce nonspecific adsorption; sugars (trehalose, sucrose) and polyols (glycerol) can improve freeze–thaw stability.
• Avoid: High concentrations of denaturants (urea, guanidinium), strong acids/bases, and most organic solvents (acetone, acetonitrile, methanol) that can precipitate or denature antibodies unless intentionally used for precipitation/purification steps.
• Filtration/sterility: If sterility is needed, use 0.22 µm PVDF filters; avoid repeated filtration that may reduce titer due to adsorption.

Selection versus alternatives (context)

• For immunoassays, match the assay buffer to downstream application (e.g., TBS-T for WB, PBS with carrier protein for ELISA). For tissue staining, include blocking proteins and appropriate permeabilizers. Composition for this SKU is not specified; check CoA before adjusting buffer systems.

Storage & Reconstitution

Item-specific facts (from Product Data)

• Storage conditions: Store at −20°C. Avoid repeated freezing and thawing.
• Shipping: Ice chest + ice pads.
• Reconstitution instructions and buffer composition: Not specified for this item; refer to CoA/Spec Sheet.

General guidance for recombinant antibodies (context; not product-specific specifications)

• Upon receipt: Inspect for any signs of warming or leakage. Centrifuge briefly to collect contents.
• Aliquoting: To avoid freeze–thaw, divide into single-use aliquots in low-bind tubes. Typical aliquots are sized for one experiment to minimize repeated cycles.
• Temperature: For long-term storage, −20°C or −80°C is standard depending on formulation. If buffer contains 40–50% glycerol, storage at −20°C (non-freezing) is common; if without cryoprotectant, store at ≤−20°C and freeze.
• Light protection: Protect from light if conjugated; conjugation status is not specified for this item.
• Reconstitution (if lyophilized): Use sterile, neutral pH buffer (e.g., PBS) to the concentration recommended on the CoA. Allow to dissolve gently at RT and mix by slow inversion; avoid vigorous vortexing to minimize aggregation.
• Short-term handling: Keep on ice during use. Do not store working dilutions for extended periods unless stability is documented.

Always consult the CoA/Spec Sheet for lot-specific concentration, buffer composition, preservative content, and any special storage notes.

Structure & Identity

Item-specific identifiers for small molecules (SMILES, InChIKey, CAS, CID) do not apply to protein antibodies. This product is a recombinant antibody preparation.

Item-specific facts (from Product Data)

• SKU: Ab100992
• Product name: Recombinant eEF1A1/EF-Tu Antibody (ExactAb™, Validated)
• Category: Antibody (research use only)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature description (antibody architecture)

• Antibody class: Typically IgG-like format for research antibodies; recombinant production implies defined amino acid sequence and lot-to-lot consistency. Exact isotype/subclass and light chain type are not specified for this item; refer to CoA/Spec Sheet.
• Structural features: Two heavy and two light chains forming a Y-shaped heterotetramer with variable regions (VH/VL) forming the paratope that recognizes epitopes on target proteins; Fc domain mediates secondary antibody recognition. For recombinant antibodies, sequence-defined variable regions are expressed in host cells (e.g., HEK293/CHO) to ensure reproducibility.
• Target epitopes: The product name indicates specificity toward eukaryotic elongation factor 1A1 (eEF1A1) and the bacterial homolog EF-Tu. Precise epitope mapping (linear vs conformational, peptide region) is not specified for this item; refer to CoA/Spec Sheet.

Notes

• No stereochemistry, rings, or functional groups are enumerated as in small-molecule entries; identity is defined by amino acid sequence and binding specificity.

Synthetic Utility

Not typically applicable. As a recombinant antibody, this product is used for biochemical detection and capture rather than as a reagent in synthetic organic or inorganic transformations.

Related practical notes (general)

• Conjugation chemistry: If end-users plan to derivatize the antibody (e.g., HRP, fluorophores, biotin), standard amine-reactive (NHS-esters), thiol-reactive (maleimides), or click-chemistry handles can be applied after appropriate buffer exchange to remove amines or thiols. The availability of free cysteines depends on reduction strategy and native disulfide pattern.
• Immobilization: Antibodies can be immobilized on activated matrices (CNBr-activated Sepharose, NHS-agarose, epoxy resins) for affinity capture of eEF1A1/EF-Tu. Optimize coupling pH and density to maintain binding activity.

Note: No conjugation state or functionalization is specified for Ab100992; treat as an unconjugated antibody unless otherwise noted on the CoA/Spec Sheet.

Target Specificity

Item-specific facts (from Product Data)

• Antigen/Target: eEF1A1/EF-Tu (eukaryotic elongation factor 1A1 and bacterial elongation factor Tu).
• Clone, isotype, host species, species reactivity, epitope, and cross-reactivity: Not specified for this item; refer to CoA/Spec Sheet.

General context

• eEF1A1 is a cytosolic translation elongation factor in eukaryotic cells; EF-Tu is the bacterial homolog. Because of homology, some antibodies may recognize conserved epitopes, but exact cross-reactivity profiles are sequence- and epitope-dependent.

Recommendations

• Verify species reactivity (human/mouse/rat or bacterial strains) and any isoform selectivity (eEF1A1 vs eEF1A2) on the CoA before planning experiments.
• Include appropriate positive controls: eukaryotic cell lysates for eEF1A1; bacterial lysates for EF-Tu. Negative controls should include knockout/knockdown or species lacking the target.

Frequently Asked Questions

What does ExactAb? mean?

ExactAb? indicates the product has been validated for use in rigorous antibody validation workflows. Validation may include positive/negative control samples, signal-to-noise testing, and protocol-specific QC. Lot-specific test data is published on the Certificate of Analysis where available.

What does Recombinant mean?

Recombinant is a defined analytical purity tier suitable for workflows requiring a specific validated property. It specifies a minimum assay percentage, controlled limits on common impurities (water, heavy metals, residue on ignition), and lot-to-lot consistency. Recombinant is one of several purity tiers — choose based on the sensitivity and regulatory requirements of your method.

How should this product be stored?

Store at ?20 °C. Avoid repeated freeze–thaw cycles. Aliquot into single-use volumes before freezing.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Which species reactivity has this antibody been validated against?

Validated reactivity is listed on the PDP and on each lot's datasheet. We validate against the most commonly tested species for the target (Recombinant eEF1A1/EF-Tu Antibody); cross-reactivity in untested species may exist but is not guaranteed. Contact technical support for specific species inquiries.